Acadia is reiterating all of its 2024 guidance provided on February 27, 2024. DAYBUE net product sales guidance in the range of $370 to $420 million. R&D expense in the range of $305 to $325 million. SG&A expense in the range of $455 to $480 million.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
- Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan